Our gene expression signature analyses in 2250 Moffitt CRC tumors, and in two independent CRC tumor datasets (Marisa (n = 585) [23], TCGA (n = 677) [47]) as well as in Medico CRC cell lines (n = 154) [24], revealed that the 13-gene MEKi “bypass”-resistance signature score was strikingly-correlated with SRC activation, as measured by two independently reported signatures measuring SRC activation/dependency [27, 28] (Figs. 2,6,7,S10a). Here, SRC is linked to colorectal carcinoma.